Por medio del Acuerdo de , la Comisión de Regulación en Salud – CRES-, introdujo ajustes al Acuerdo , por medio del cual se. acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. P P 11 1 P(|racu|ra |loslalo) 15 rd de oase lao|ela o cápsu|a. P Z0 1 0u|r|ra d|c|o(r|d(alo rd/2 rL so|uc|ór |rveclao|e. P 10 1 0u|r|ra.
|Published (Last):||17 June 2013|
|PDF File Size:||1.79 Mb|
|ePub File Size:||9.79 Mb|
|Price:||Free* [*Free Regsitration Required]|
acuerdo 029 de 2011 cres pdf
Dyslipidemias; anticholesteremic agents, efficacy; cardiovascular diseases; lovastatin; gemfibrozil; Colombia. Fitzner K, Heckinger E.
The above findings support increasing the dose of the lipid-lowering therapy based on clearly defined objectives 16, The goal of the ATP III is for the Framingham score to quantify each patient’s “absolute risk of coronary heart disease over 10 years” during routine medical consultation 7, 9.
In this study the controlled patients received doses of lovastatin that were significantly higher than those administered to the uncontrolled patients, but all patients received DDDs lower than the recommended values, as has been reported elsewhere These cities were selected for convenience because they had relevant and reliable databases available.
The use of lipid-lowering drugs was examined, and the number of patients receiving monotherapy was as follows: Issues and evidence for the management of dyslipidaemia in primary care. This is worrisome because the study sample was from a patient population with easy access to medication. Rev Panam Salud Publica.
acuerdo de cres pdf – PDF Files
Ministry of Health, Colombia. Most patients in the present study had other risk factors that increased the difficulty of dyslipidemia management and control, especially for asymptomatic diseases, such as hypertension, diabetes, and hypothyroidism; and the use of additional medications for each of these problems results in patients with polypharmacy, as reported by another study Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men.
For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs. Worldwide, heart disease and stroke represent the crfs most common causes of death, with dyslipidemia being a primary crew factor 1, 2. The present study, which afuerdo that Information on sociodemographic and anthropometric characteristics, risk factors, and pharmacological and laboratory variables were obtained from medical records.
This can be correlated with a lack of knowledge on the part of many physicians around what is a desirable goal based on the patient’s risk and what drug and dose should be prescribed to 09 it Measurements of LDL-C at treatment initiation were found for patients To access other dyslipidemia control medications, the prescribing physician makes a special request through each Empresa Promotora de Salud health services provider, EPS to the Scientific Technical Committee CTC 11, LDL-C measurements taken in the 6 months prior to the study were available for cases The characteristics of the population analyzed are shown in Table 1.
From a total of 8 patients in 10 cities, cress random sample of was stratified according to dyslipidemia. Therapy adherence was determined by the degree to which the patient complied with the recommendations recorded by the doctor in the medical record.
Furthermore, the importance of the starting dose to the overall effectiveness of the therapy has been underscored by a study showing that the percentage reduction in LDL-C levels achieved with the initial dose of statins was strongly correlated with the proportion of patients who maintained their goals at 54 weeks; therefore, it is recommended that therapy start at a dose that should achieve the goal, and if insufficient, be increased significantly to achieve it Under these circumstances, strategies aimed at identifying individuals with dyslipidemia and implementing primary and crew CVD preventive measures have become health priorities.
Recommendations for the management of dyslipidemia and prevention of cardiovascular disease: In cases where the target LDL-C level was not being met, and if all patients are considered to have complied with the adjustments, then therapy modifications acerdo insufficient 19, Detection, evaluation, and treatment of high blood cholesterol in adults.
Unfortunately, dyslipidemia treatment meets the three conditions that are associated with poor adherence: Lipid concentrations and the use of lipid lowering drugs: Definition of effectiveness The effectiveness of lipid-lowering therapies was established based on the following groups, defined according to the ATP III goal set and whether it was achieved or not: Table 4 shows the results of the bivariate analysis comparing the subgroup of patients with controlled dyslipidemia to the uncontrolled subgroup, belonging to risk group 2.
Acuerdo by Yennǐfer Morales Velez on Prezi
A statistically-significant association was found between the rate of dyslipidemia control and the following variables: Data collection The quality of the patient records was reviewed by two physicians. In this study, however, the proportion of patients who claim to have followed the correct treatment was relatively high, which is cges contrast to the low rate of metabolic control When these recommendations have been rigorously implemented, the results are fewer cardiovascular events, improved quality of life, and lower dyslipidemia sequelae-related costs Send correspondence to Jorge Enrique Machado-Alba, email: This was a cross-sectional retrospective study of patients who were: Sample size calculation and power analysis: Any incomplete record was replaced by the complete record of another randomized patient from the same city and of the same sex and age group.
The chi-square test was used to establish associations between variables based on the risk subgroup.